{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:10:30Z","timestamp":1789567830680,"version":"build-2803163510"},"reference-count":13,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.3201\/eid2810.220625","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T14:40:15Z","timestamp":1663944015000},"page":"2060-2063","source":"Crossref","is-referenced-by-count":9,"title":["Two Cases of Lassa Fever Successfully Treated with Ribavirin and Adjunct Dexamethasone for Concomitant Infections"],"prefix":"10.3201","volume":"28","author":[{"given":"Sylvanus","family":"Okogbenin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Erameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Okoeguale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osahogie","family":"Edeawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esele","family":"Ekuaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Iraoyah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Agho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Groger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benno","family":"Kreuels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Oestereich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femi O.","family":"Babatunde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Akhideno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ramharter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Omansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid2810.220625-202209201651-R1","doi-asserted-by":"publisher","first-page":"e0008589","DOI":"10.1371\/journal.pntd.0008589","article-title":"Systematic review and meta-analysis of the epidemiology of Lassa virus in humans, rodents and other mammals in sub-Saharan Africa.","volume":"14","author":"Kenmoe","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"key-10.3201\/eid2810.220625-202209201651-R2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever. Effective therapy with ribavirin.","volume":"314","author":"McCormick","year":"1986","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2810.220625-202209201651-R3","unstructured":"Nigeria Center for Disease Control. National Guideline for Lassa Fever Case Management. 2018 [cited 2022 Feb 2]. https:\/\/ncdc.gov.ng\/themes\/common\/docs\/protocols\/92_1547068532.pdf"},{"key":"key-10.3201\/eid2810.220625-202209201651-R4","unstructured":"World Health Organization. Clinical management of patients with viral haemorrhagic fever: a pocket guide for front-line health workers: interim emergency guidance for country adaptation. 2016 [cited 2022 Feb 2]. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/205570\/9789241549608_eng.pdf"},{"key":"key-10.3201\/eid2810.220625-202209201651-R5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijid.2019.07.015","article-title":"Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis.","volume":"87","author":"Eberhardt","year":"2019","journal-title":"Int J Infect Dis"},{"key":"key-10.3201\/eid2810.220625-202209201651-R6","doi-asserted-by":"publisher","first-page":"e0009522","DOI":"10.1371\/journal.pntd.0009522","article-title":"Time to reconsider the role of ribavirin in Lassa fever.","volume":"15","author":"Salam","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"key-10.3201\/eid2810.220625-202209201651-R7","doi-asserted-by":"publisher","first-page":"e036936","DOI":"10.1136\/bmjopen-2020-036936","article-title":"Prospective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria.","volume":"10","author":"Erameh","year":"2020","journal-title":"BMJ Open"},{"key":"key-10.3201\/eid2810.220625-202209201651-R8","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1016\/S2214-109X(20)30518-0","article-title":"Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort study.","volume":"9","author":"Duvignaud","year":"2021","journal-title":"Lancet Glob Health"},{"key":"key-10.3201\/eid2810.220625-202209201651-R9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000490374","article-title":"Acute Lassa virus encephalitis with Lassa virus in the cerebrospinal fluid but absent in the blood: a case report with a positive outcome.","volume":"10","author":"Okokhere","year":"2018","journal-title":"Case Rep Neurol"},{"key":"key-10.3201\/eid2810.220625-202209201651-R10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1086\/322033","article-title":"Lassa fever encephalopathy: Lassa virus in cerebrospinal fluid but not in serum.","volume":"184","author":"G\u00fcnther","year":"2001","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid2810.220625-202209201651-R11","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1473-3099(20)30737-4","article-title":"Factors associated with progression to death in patients with Lassa fever in Nigeria: an observational study.","volume":"21","author":"Strampe","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid2810.220625-202209201651-R12","doi-asserted-by":"publisher","first-page":"e01367","DOI":"10.1128\/JVI.01367-20","article-title":"Severe human Lassa fever is characterized by nonspecific T-cell activation and lymphocyte homing to inflamed tissues.","volume":"94","author":"Port","year":"2020","journal-title":"J Virol"},{"key":"key-10.3201\/eid2810.220625-202209201651-R13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19.","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/28\/10\/22-0625_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:53:41Z","timestamp":1732989221000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/28\/10\/22-0625_article.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"URL":"https:\/\/doi.org\/10.3201\/eid2810.220625","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}